Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?
Clinical Infectious Diseases · 03.11.2026
DOI: 10.1093/cid/ciag696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.11.2026. Verfasst von Anne S Peters und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genomics & Resistant Microbes (GeRM), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarroll….
Abstract (Originalsprache)
Background
The IDSA guidance suggests treating Enterobacterales resistant to ertapenem but susceptible to imipenem or meropenem with a susceptible carbapenem in the absence of carbapenemase production; however, clinical outcomes data are limited.
Methods
We conducted a multicenter prospective cohort study of hospitalized patients with invasive ceftriaxone-resistant Enterobacterales infections, comparing 30-day mortality between ertapenem-susceptible (ETP-S) and ertapenem-resistant (ETP-R) isolates. ETP-S isolates with an ESBL/AmpC phenotype served as the comparator because carbapenems are reliably active against these organisms. Carbapenem susceptibility was confirmed by broth microdilution. Inclusion criteria included: (1) susceptibility to imipenem or meropenem, (2) absence of carbapenemase genes, and (3) >72 hours of definitive therapy with imipenem or meropenem. Inverse probability weighting (IPW) adjusted for baseline differences, and logistic regression estimated odds ratios with 95% confidence intervals.
Results
Among 374 patients, 238 (64%) were infected with ETP-S and 136 (36%) ETP-R isolates. Baseline characteristics were balanced after IPW. ETP-R infection was associated with higher 30-day mortality (OR 2.24, 95% CI 1.26-3.98, p=0.006). Similarly, 14-day and in-hospital mortality were significantly higher among patients with ETP-R infections. The highest mortality was observed among patients with isolates resistant to two carbapenems (e.g., ertapenem and meropenem). Genomic analyses demonstrated enrichment of porin alterations and more non-carbapenemase β-lactamase genes (e.g., blaCTX-M, blaOXA-10) in ETP-R isolates.
Conclusion
Among patients with Enterobacterales bacteremia treated with imipenem or meropenem, ETP-R isolates were associated with higher mortality than ETP-S isolates, challenging current guidance. This likely reflects combined porin loss and increased β-lactamase activity, potentially resulting in partial hydrolysis of higher-order carbapenems despite in vitro susceptibility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomics & Resistant Microbes (GeRM), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Chile.
- Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance, Santiago, Chile.
- Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats (SENTINET), Santiago, Chile.
- Hospital Padre Hurtado, Santiago, Chile.
- Hospital Puerto Montt, Puerto Montt, Chile.
- Departamento de Laboratorios Clínicos, Escuela de Medicina, Universidad Católica de Chile, Santiago, Chile.
ORCID-Profile: Anne S Peters, Lorena Diaz, José R W Martínez, Lina Rivas, William R Miller, Pranita D Tamma, José M Munita
Zitieren
APA
Peters, A. S., Diaz, L., Martínez, J. R. W., Rojas, P., Rioseco, M. L., Rivas, L., Garcia, P., Miller, W. R., Tamma, P. D., & Munita, J. M. (2026). Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag696
Vancouver
Peters AS, Diaz L, Martínez JRW, Rojas P, Rioseco ML, Rivas L, et al. Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag696
BibTeX
@article{Peters2026,
author = {Peters, Anne S and Diaz, Lorena and Martínez, José R W and Rojas, Pamela and Rioseco, María L and Rivas, Lina and Garcia, Patricia and Miller, William R and Tamma, Pranita D and Munita, José M},
title = {Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag696}
}
EUVIMED